DK2189162T3 - Fremgangsmåder til behandling af cellulære proliferative forstyrrelser - Google Patents

Fremgangsmåder til behandling af cellulære proliferative forstyrrelser

Info

Publication number
DK2189162T3
DK2189162T3 DK10153374.3T DK10153374T DK2189162T3 DK 2189162 T3 DK2189162 T3 DK 2189162T3 DK 10153374 T DK10153374 T DK 10153374T DK 2189162 T3 DK2189162 T3 DK 2189162T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
proliferative disorders
cellular proliferative
cellular
Prior art date
Application number
DK10153374.3T
Other languages
English (en)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK2189162T3 publication Critical patent/DK2189162T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/115Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135Respiratory syncytial virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/14Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
DK10153374.3T 2000-11-09 2001-10-26 Fremgangsmåder til behandling af cellulære proliferative forstyrrelser DK2189162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24672800P 2000-11-09 2000-11-09
EP01980092A EP1332366B1 (en) 2000-11-09 2001-10-26 Methods for the Assessment of Cellular Proliferative Disorders

Publications (1)

Publication Number Publication Date
DK2189162T3 true DK2189162T3 (da) 2014-02-03

Family

ID=22931950

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10153374.3T DK2189162T3 (da) 2000-11-09 2001-10-26 Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK01980092.9T DK1332366T3 (da) 2000-11-09 2001-10-26 Fremgangsmåde til vurdering af cellulære proliferative forstyrrelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01980092.9T DK1332366T3 (da) 2000-11-09 2001-10-26 Fremgangsmåde til vurdering af cellulære proliferative forstyrrelser

Country Status (16)

Country Link
US (3) US7052832B2 (da)
EP (2) EP1332366B1 (da)
JP (2) JP4146725B2 (da)
AR (1) AR031281A1 (da)
AT (1) ATE472733T1 (da)
AU (2) AU1202202A (da)
BR (1) BR0115235A (da)
CA (1) CA2428206C (da)
DE (1) DE60142485D1 (da)
DK (2) DK2189162T3 (da)
ES (2) ES2445704T3 (da)
IL (1) IL154881A0 (da)
MX (1) MXPA03004029A (da)
NZ (1) NZ524937A (da)
WO (1) WO2002039117A1 (da)
ZA (1) ZA200302086B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int WEAKEN REOVIRUS
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
AU2007215328A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
WO2008031230A1 (en) * 2006-09-15 2008-03-20 Dalhousie University Methods of determining susceptibility of cells to reovirus infection and methods for treating cellular proliferative disorders with reovirus
CA2678721C (en) 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
MX2010003556A (es) * 2007-10-22 2010-04-21 Oncolytics Biotech Inc Regimen de tratamiento para trastornos proliferantes.
TWI399369B (zh) 2008-04-02 2013-06-21 Nat Defense Medical Ct 咪唑蒽醌衍生物及其合成方法
WO2009143611A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
ES2952055T3 (es) 2015-01-26 2023-10-26 Ottawa Hospital Res Inst Composiciones y métodos para la sensibilización viral
SI3518948T1 (sl) 2016-10-03 2023-09-29 Ottawa Hospital Research Institute Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov
CA2971832A1 (en) * 2017-06-23 2018-12-23 Roy Duncan Recombinant oncolytic viruses for treatment of metastatic cancers
CN111373032A (zh) 2017-11-24 2020-07-03 渥太华医院研究所 用于增强干扰素敏感性病毒的生产、生长、扩散或溶瘤和免疫治疗功效的组合物和方法
US20210196813A1 (en) * 2019-12-27 2021-07-01 Rush University Medical Center Utilizing Vaccines to Treat Cancer and Enhance the Success Rate of Cancer Immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders

Also Published As

Publication number Publication date
US7763252B2 (en) 2010-07-27
US20060172288A1 (en) 2006-08-03
US20080057073A1 (en) 2008-03-06
JP2004512385A (ja) 2004-04-22
ES2347523T3 (es) 2010-11-02
DK1332366T3 (da) 2010-08-02
AU2002212022B2 (en) 2006-03-30
ZA200302086B (en) 2004-03-15
US20020086284A1 (en) 2002-07-04
BR0115235A (pt) 2003-10-14
EP2189162B1 (en) 2013-11-27
AU1202202A (en) 2002-05-21
NZ524937A (en) 2004-10-29
DE60142485D1 (de) 2010-08-12
JP4146725B2 (ja) 2008-09-10
EP2189162A1 (en) 2010-05-26
CA2428206A1 (en) 2002-05-16
IL154881A0 (en) 2003-10-31
ATE472733T1 (de) 2010-07-15
US7052832B2 (en) 2006-05-30
JP2008268200A (ja) 2008-11-06
HK1142833A1 (en) 2010-12-17
ES2445704T3 (es) 2014-03-04
EP1332366B1 (en) 2010-06-30
AR031281A1 (es) 2003-09-17
WO2002039117A1 (en) 2002-05-16
MXPA03004029A (es) 2004-02-12
EP1332366A1 (en) 2003-08-06
US7815914B2 (en) 2010-10-19
CA2428206C (en) 2005-09-27

Similar Documents

Publication Publication Date Title
DK1156813T3 (da) Reovirus til behandling af cellulære proliferative lidelser
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
IL153846A0 (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1328538T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af 7-substituerede antiöstrogener
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser